We have also provided a summary of the additional PPAR agonists’ roles in regulating bile acid metabolism; these newer agonists are currently in clinical development for the treatment of cholestatic liver diseases, including elafibranor, the first PPAR agonist FDA-approved for second-line treatment of PBC. This evidence concerns the gene PPARA and primary biliary cholangitis.